Kymos Acquires Germany’s Prolytic
![](/46/pdcnewsitem/11/30/47/kymos-prolytic.gif)
Dorothee Krone, managing director of Prolytic, and Joan Puig de Dou, CEO of Kymos, sign the merger contract for Kymos and Prolytic to become Kymos Group. © Kymos Group
Kymos, a Contract Research Organisation (CRO) and member of CataloniaBio & HealthTech, has bought German company Prolytic GmbH in order to strengthen its activity in the biologics and advanced therapies market. The company previously acquired Italian firm Pharmaprogress in 2016.
Germany: Kymos creates pan-European CRO
![Kymos Pharma Services, S.L.](https://www.cphi-online.com/c254638th_S-comp254638.jpg)
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance